News

On September 11, 2026, the FGBI “ARRIAH” received registration documents for an inactivated emulsion vaccine against avian salmonellosis. Institute specialists developed the vaccine and became the first in the country to successfully complete the registration dossier in accordance with EAEU requirements.

Registration under EAEU requirements involves assessing the product for compliance with unified requirements for its quality, safety, and efficacy. This allows the registered product to be used within the single market for veterinary medicinal products of the EAEU member states.

The new vaccine against avian salmonellosis developed at the FGBI “ARRIAH” induces immunity in birds as early as three weeks after the first vaccination. Two routes of administration are provided for: subcutaneous and intramuscular.

In addition, as part of the preclinical studies, a large-scale trial was conducted to assess the level and duration of transovarial immunity in chicks, which protects them from infection for at least 14 days after hatching. Two-dose immunization of layers is recommended to build robust immunity lasting at least 14 months: the first dose at 8–9 weeks of age, the second 4–5 weeks before the onset of lay.

Furthermore, as part of the research, ELISA test kits were developed for each serotype of the pathogen whose antigens are included in the vaccine, enabling quantitative assessment of the immunity level in vaccinated birds. The developed test kits will allow poultry farms to monitor the immune status of their flocks after vaccination free of charge.

The development and registration of the new domestic vaccine will provide poultry farms with an additional tool to protect against salmonellosis, reduce the risk of disease spread, and improve the effectiveness of preventive measures.

For reference:

Salmonellosis is an infectious disease caused by bacteria of the genus Salmonella. The disease is dangerous for young poultry: in its acute form, it can cause high mortality, stunted growth, and delayed development. In adult birds, the infection often runs a subclinical course, yet the birds may remain carriers and shed the pathogen.

Certain Salmonella species are of public health significance, since poultry and poultry products can become sources of human infection. This is precisely why preventing the infection at the poultry farm level matters not only for preserving flocks and production performance, but also for ensuring the biological safety of products.